Spots Global Cancer Trial Database for sunitinib malate
Every month we try and update this database with for sunitinib malate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sunitinib Malate in Treating Patients With Kidney Cancer | NCT00943839 | Kidney Cancer | sunitinib malat... laboratory biom... pharmacological... | 18 Years - | Centre Antoine Lacassagne | |
| Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) | NCT00495625 | Liver Cancer | Sunitinib Malat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma | NCT00392496 | Adult Diffuse L... Recurrent Adult... Stage IV Adult ... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma | NCT00521092 | AIDS-related Ka... Classic Kaposi ... | sunitinib malat... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery | NCT01061411 | Clear Cell Sarc... Recurrent Renal... Stage III Renal... Stage IV Renal ... | Dalteparin Pharmacological... Sunitinib Malat... | 18 Years - | Roswell Park Cancer Institute | |
| Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | NCT00372567 | Gastrointestina... | sunitinib malat... imatinib mesyla... | 18 Years - | Pfizer | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer | NCT00417885 | Breast Neoplasm... | exemestane sunitinib malat... | 18 Years - | Pfizer | |
| Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer | NCT00979992 | Ovarian Clear C... Recurrent Ovari... | Laboratory Biom... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Kidney Cancer | NCT00943839 | Kidney Cancer | sunitinib malat... laboratory biom... pharmacological... | 18 Years - | Centre Antoine Lacassagne | |
| Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | NCT00397787 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | NCT00451048 | Chronic Myelomo... de Novo Myelody... Myelodysplastic... Secondary Myelo... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer | NCT00524186 | Esophageal Canc... Gastric Cancer | fluorouracil irinotecan hydr... leucovorin calc... sunitinib malat... flow cytometry pharmacological... | - 120 Years | Roswell Park Cancer Institute | |
| Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer | NCT00541008 | Kidney Cancer | sunitinib malat... | 18 Years - 120 Years | UNICANCER | |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | NCT00748163 | Lung Cancer | paclitaxel albu... sunitinib malat... | 18 Years - 120 Years | Masonic Cancer Center, University of Minnesota | |
| Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer | NCT00792025 | Bladder Cancer Transitional Ce... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma | NCT00392444 | Advanced Malign... Recurrent Malig... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer | NCT00931450 | Breast Cancer | exemestane sunitinib malat... placebo | - | National Cancer Institute (NCI) | |
| Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | NCT01185366 | Kidney Cancer | Everolimus Sunitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy | NCT00693992 | Stage IIIB Lung... Stage IV Non-Sm... | Laboratory Biom... Placebo Quality-of-Life... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | NCT01664182 | Advanced Renal ... Advanced Sarcom... Stage III Renal... Stage IV Renal ... | Bevacizumab Pazopanib Hydro... Sorafenib Tosyl... Sunitinib Malat... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow | NCT00824538 | Breast Cancer | sunitinib malat... flow cytometry immunohistochem... laboratory biom... | 18 Years - 120 Years | University of California, San Francisco | |
| Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment | NCT00453310 | Extragonadal Ge... Ovarian Cancer Teratoma Testicular Germ... | sunitinib malat... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | NCT01243359 | Clear Cell Rena... Recurrent Renal... Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ... Unspecified Adu... | sunitinib malat... bevacizumab pharmacological... laboratory biom... fluorine F 18 f... positron emissi... computed tomogr... | 18 Years - | National Cancer Institute (NCI) | |
| Sutent + Taxol for Advanced Esophageal Cancer | NCT00730353 | Esophageal Canc... | Sunitinib malat... Paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer | NCT00631527 | Prostate Cancer | Leuprolide Goserelin Sunitinib Malat... Casodex Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer | NCT00375674 | Kidney Neoplasm... | Sunitinib malat... Placebo | 18 Years - | Pfizer | |
| Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer | NCT00393939 | Breast Neoplasm... | Sunitinib malat... Taxotere | 18 Years - | Pfizer | |
| Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer | NCT00849186 | Kidney Cancer | sunitinib malat... neoadjuvant the... therapeutic con... | 18 Years - | Roswell Park Cancer Institute | |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | NCT01835158 | Clear Cell Rena... Metastatic Kidn... Stage III Renal... Stage IV Renal ... | Cabozantinib S-... Laboratory Biom... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan) | NCT00716625 | Carcinoma, Rena... | sunitinib malat... | 0 Days - | Pfizer | |
| Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery | NCT00936832 | Colorectal Canc... Metastatic Canc... | FOLFIRI regimen fluorouracil irinotecan hydr... leucovorin calc... sunitinib malat... laboratory biom... pharmacogenomic... pharmacological... | 18 Years - 120 Years | Federation Francophone de Cancerologie Digestive | |
| Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery | NCT00326898 | Clear Cell Rena... Stage I Renal C... Stage II Renal ... Stage III Renal... | Laboratory Biom... Placebo Quality-of-Life... Sorafenib Tosyl... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer | NCT00616122 | Breast Cancer | cyclophosphamid... methotrexate sunitinib malat... laboratory biom... | 18 Years - 120 Years | University of California, San Francisco | |
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | NCT02060370 | Genitourinary C... Kidney Cancer | Sunitinib Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Perifosine + Sunitinib Malate for Patients With Advanced Cancers | NCT00399152 | Renal Cancer GIST | Perifosine Sunitinib Malat... | 18 Years - | AEterna Zentaris | |
| Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | NCT00453154 | Extensive Stage... Recurrent Lung ... | Carboplatin Cisplatin Etoposide Laboratory Biom... Placebo Adminis... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer | NCT00541008 | Kidney Cancer | sunitinib malat... | 18 Years - 120 Years | UNICANCER | |
| Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | NCT00513695 | Inflammatory Br... Male Breast Can... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | sunitinib malat... paclitaxel doxorubicin hyd... cyclophosphamid... filgrastim therapeutic con... laboratory biom... flow cytometry | - | University of Washington | |
| Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy | NCT00672594 | Prostate Cancer Prostatectomy | Sunitinib Malat... | 18 Years - | Duke University | |
| Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma | NCT00462982 | Kidney Cancer Melanoma (Skin) Metastatic Canc... | sunitinib malat... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors | NCT00573404 | Gastrointestina... | imatinib mesyla... sunitinib malat... pharmacological... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). | NCT00716820 | Gastrointestina... | SUNITINIB MALAT... | 17 Years - | Pfizer | |
| Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction | NCT00891878 | Adenocarcinoma ... Esophageal Canc... | capecitabine sunitinib malat... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | NCT02779283 | Acute Lymphobla... Acute Myeloid L... | Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Hyd... Idarubicin Idelalisib In Vitro Kinase... Leucovorin Calc... Methotrexate Methylprednisol... Ponatinib Hydro... Rituximab Ruxolitinib Pho... Sorafenib Tosyl... Sunitinib Malat... Vincristine Sul... | 18 Years - 64 Years | OHSU Knight Cancer Institute | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery | NCT00381641 | Differentiated ... Recurrent Thyro... Refractory Thyr... Stage III Thyro... Stage III Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Thyro... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Thyro... Stage IVC Thyro... Stage IVC Thyro... Thyroid Gland O... Unresectable Th... | Laboratory Biom... Pharmacogenomic... Sunitinib Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC | NCT00859339 | Transitional Ce... | Gemcitabine Cisplatin Sunitinib Malat... Radical Cystect... | 18 Years - | Hoosier Cancer Research Network | |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck | NCT00906360 | Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Untreated Metas... | sunitinib malat... pharmacological... 3-dimensional c... cetuximab | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Recurrent Malignant Gliomas | NCT00499473 | Adult Anaplasti... Adult Diffuse A... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Oligodend... Adult Pineal Gl... | sunitinib malat... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer | NCT00338884 | Carcinoma, Rena... | Sunitinib malat... | - | Pfizer | |
| A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor | NCT01396148 | Gastrointestina... | sunitinib malat... sunitinib malat... | 6 Years - 20 Years | Pfizer | |
| Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer | NCT01026337 | Renal Cell Carc... Stage III Renal... Stage IV Renal ... | mutation analys... pharmacological... dynamic contras... sunitinib malat... immunohistochem... laboratory biom... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer | NCT00853125 | Kidney Cancer | therapeutic all... sunitinib malat... | 18 Years - 75 Years | Rutgers, The State University of New Jersey | |
| Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer | NCT00849186 | Kidney Cancer | sunitinib malat... neoadjuvant the... therapeutic con... | 18 Years - | Roswell Park Cancer Institute | |
| A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors | NCT00428597 | Carcinoma, Isle... Carcinoma, Panc... | sunitinib malat... Placebo | 18 Years - | Pfizer | |
| Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer | NCT00555672 | Stomach Neoplas... | 5-fluorouracil cisplatin sunitinib malat... | 18 Years - | Pfizer | |
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | NCT02060370 | Genitourinary C... Kidney Cancer | Sunitinib Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | NCT00372567 | Gastrointestina... | sunitinib malat... imatinib mesyla... | 18 Years - | Pfizer | |
| Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer | NCT00853125 | Kidney Cancer | therapeutic all... sunitinib malat... | 18 Years - 75 Years | Rutgers, The State University of New Jersey | |
| Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | NCT00478426 | Endometrial Ade... Endometrial End... Endometrial Ser... Recurrent Uteri... Stage IVA Uteri... Stage IVB Uteri... Uterine Carcino... Uterine Corpus ... | Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Sunitinib in Treating Patients With Solid Tumors | NCT00357318 | Unspecified Adu... | sunitinib malat... bevacizumab pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) | NCT00495625 | Liver Cancer | Sunitinib Malat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | NCT00748163 | Lung Cancer | paclitaxel albu... sunitinib malat... | 18 Years - 120 Years | Masonic Cancer Center, University of Minnesota | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer | NCT01024205 | Kidney Cancer | sunitinib malat... laboratory biom... adjuvant therap... neoadjuvant the... therapeutic con... | 18 Years - | National Cancer Institute (NCI) | |
| Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). | NCT00716820 | Gastrointestina... | SUNITINIB MALAT... | 17 Years - | Pfizer | |
| Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow | NCT00824538 | Breast Cancer | sunitinib malat... flow cytometry immunohistochem... laboratory biom... | 18 Years - 120 Years | University of California, San Francisco | |
| Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors | NCT00462553 | Adenocarcinoma ... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... Unspecified Adu... | sunitinib malat... gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy | NCT00329043 | Prostate Cancer | LHRH Agonist Sunitinib Malat... Radical Prostat... | - | M.D. Anderson Cancer Center | |
| Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) | NCT01089088 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... sunitinib malat... | 16 Years - 120 Years | Cardiff University | |
| Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer | NCT01740154 | Fatigue Recurrent Renal... Stage IV Renal ... | transcranial ma... electromyograph... survey administ... sunitinib malat... | 18 Years - | Case Comprehensive Cancer Center | |
| Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | NCT00378911 | Recurrent Uteri... Uterine Leiomyo... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
